UBS on Pharma
Generic GLP-1 likely a highly competitive market; assume sector coverage
Sun Pharma – (Buy) – Looks well-positioned, with innovative medicines and a robust pipeline to support earnings
Cipla – (Neutral) – To face near-term lanreotide supply disruptions, but product launches from late FY27E are healthy









